Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) announced its quarterly earnings results on Monday. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.18 by $0.18, Zacks reports. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 13.56%.
Shionogi & Co., Ltd. Unsponsored ADR Stock Performance
OTCMKTS SGIOY opened at $9.04 on Monday. The company has a current ratio of 1.58, a quick ratio of 1.46 and a debt-to-equity ratio of 0.01. Shionogi & Co., Ltd. Unsponsored ADR has a twelve month low of $7.65 and a twelve month high of $12.00. The stock has a market capitalization of $15.39 billion, a price-to-earnings ratio of 11.30, a PEG ratio of 3.55 and a beta of 0.09. The stock has a 50-day moving average of $8.82 and a 200 day moving average of $9.88.
Analysts Set New Price Targets
A number of research analysts have issued reports on SGIOY shares. Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. Finally, The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy”.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Read More
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- 3 Humanoid Robot ETFs to Ride a Speculative Trend
- Bearish Pressure Is Building Around These 3 Stocks
- 3 Low-Volatility Plays Quietly Making a Name For Themselves
- ASML’s Dividend Growth Adds a Quiet Income Angle to Its AI Chip Story
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
